Kornimate/medical-research-clean huggingface dataset:
microbiota community of irritable bowel syndrome in episodes and remission phase

Conditions: Irritable Bowel Syndrome

Summary: analyze microbiota community of irritable bowel syndrome in episodes phase and remission phase.

the pathophysiology of ibs is incompletely understood, it may involve an altered intestinal microbiota. since the microflora composition of ibs is various in different studies, the investigators plan to compare the intestinal microbiota of ibs patients in episodes phase and remission phase with healthy controls,trying to find the difference.

Eligibility criteria:
inclusion criteria: * the presence of rome iii criteria for ibs ; * patients scheduled for colonoscopy examination or having negative screening examinations * aged between 18 and 65 years old exclusion criteria: * antibiotic, probiotic or laxative usage within 4 weeks. * organic gastrointestinal diseases * severe systematic disease: diabetes mellitus, hepatic, renal or cardiac dysfunction, thyroid disease or tumor etc. * pregnancy or lactation. * previous major or complicated abdominal surgery. * severe endometriosis and dementia

Keywords: microbiota community ibs
pancreatic intraepithelial neoplasia (panin) and the association with recurrence of pancreatic adenocarcinoma

Conditions: Pancreatic Cancer

Summary: the research purpose of this project is to create a registry, and blood and tissue bank for individuals at high-risk for pancreatic cancer. we plan to conduct histopathological and molecular analysis of resected pancreatic tissue prospectively collected from a cohort of pancreatic cancer patients.

pancreatic cancer is the fifth leading cause of cancer-related death in the united states. in order to improve outcomes of this disease, significant research efforts have focused on understanding the changes that occur in the pancreas prior to tumor occurrence. the types of changes most often associated with tumor have been named pancreatic intraepithelial neoplasia (panin). it is not yet clear how to identify the panin lesions most likely to develop into cancer and the length of time required for this progression. in order to evaluate these questions, we are interested in examining the microscopic and genetic characteristics of panin lesions in two "high-risk" patients: 1) patients who underwent surgery for pancreatic cancer and developed tumor recurrence after surgery and 2) patients with a strong family history of pancreatic cancer or with a genetic syndrome that puts them at risk for pancreas cancer. the surgical specimens from these patients will be evaluated by a pathologist for evidence of widespread panin lesions. in addition, panin lesions will be tested for abnormalities in several major genes that are known to be important in pancreatic cancer.

Eligibility criteria:
inclusion criteria: * tissue-confirmed diagnosis of pancreatic adenocarcinoma. * underwent surgical resection for adenocarcinoma at columbia-presbyterian medical center with pathologically negative surgical margins. * enrolled in our pancreatic cancer registry and tissue bank protocol (aaaa-6154). * have at least 2 relatives (of whom one must be first-degree relative) with pancreatic cancer, or have been diagnosed with a a genetic syndrome which is associated with pancreatic cancer (among the included syndromes include brca1/2, fammm, peutz-jeghers, hnpcc, hereditary pancreatitis) -or- have radiological or pathological (fine needle aspirate or surgical biopsy) evidence of local tumor recurrence following surgery. exclusion criteria: * metastatic disease discovered at presentation or on recurrence (exception is the familial pdc patients) * positive surgical margins. * lack of clinical followup at one year following surgery

Keywords: pancreatic intraepithelial neoplasia (panin) pancreatic cancer recurrence of pancreatic cancer field effect genetic mutations in pancreatic cancer
st-segment elevation as an af endophenotype

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to look for a similarity in people's genes that may help understand which people could benefit from certain drugs for the treatment of atrial fibrillation (af).

current drug therapies to suppress af are incompletely and unpredictably effective and carry significant (albeit generally small) risks of serious adverse effects, including drug-induced long qt syndrome (dilqts), other forms of proarrhythmia, increased mortality through uncertain mechanisms, and extracardiac toxicity. identification of clinical and genetic subtypes of af will permit stratification of therapeutic approaches and thereby facilitate the practice of personalized medicine. furthermore, limited success of drug therapy and increase in drug toxicity in af is probably because the arrhythmia represents a final common pathway of multiple initiating mechanisms, including some that are genetically-defined. identifying specific intermediate phenotypes ("endophenotypes") associated with defined clinical courses in af represents a potential method to systematically subtype patients by underlying mechanism and represents a much-needed clinical advance. clinical endophenotypes that have been studied include atrial fibrillatory rate, prolonged signal-averaged p-wave duration, and biomarker profiles. the endophenotype we will study here is right precordial st segment elevation, seen not only in brugada syndrome (brs) (where it is unmasked by sodium channel blocking drugs) but also commonly in early-onset ('lone') af and in patients with af-associated rare variants in genes encoding the cardiac sodium channel α- or β-subunits. taken together these data suggest the hypothesis to be tested in this study, that variants in multiple genes can culminate in a similar af-prone substrate by reducing sodium current that can be identified by screening for baseline or manifest right precordial st segment elevation endophenotype after sodium channel block with intravenous procainamide.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * undergoing af ablation at vanderbilt or mgh exclusion criteria: * patients taking membrane active anti-arrhythmic drugs with sodium channel blocking properties (amiodarone, dronedarone, flecainide, propafenone) at the time of the ablation * patients with a history of brugada syndrome or type 1 brugada ecg pattern on the baseline ecg * patients with a history of drug-induced torsades de pointes * patients with a known history of hypersensitivity to procainamide, procaine or related drugs * patients with a history of systemic lupus erythematosus and myasthenia gravis * patients with a history of second degree av block (mobitz type ii) or third degree av block * women of child-bearing potential unless post-menopausal, surgically sterile, or have a negative pregnancy test day on the day of procedure * patients with dual chamber pacemakers or implantable defibrillators requiring ventricular pacing (uninterpretable ecg) * patients unable to give informed consent

Keywords: atrial fibrillation st elevation genotype
evaluation of the stroke caregiver education and support program

Conditions: Stroke

Summary: the study will be evaluating to a 4 week education and support program for stroke caregivers. the 4 week program will provide education, information, and strategies for dealing with areas that caregivers may find challenging in their caregiving role. the study will evaluate the effectiveness of the program to decrease the caregiver's stress, strain and burden, increase the caregiver's knowledge of strategies and community services and increase their role satisfaction as a stroke caregiver and quality of life two weeks after the program and 6 months after the program.

the modules in the program are: 1) program introduction, sharing caregiving stories and an introduction to self management; 2) community connections; session 3 and 4 are chosen by the participants during session 1 from 6 possible options: communication in your relationship; cognition, memory and personhood; dealing with your emotions; managing your stress; changing roles in your relationships and how to be caregiver smart? the programs provides education, information and strategies to deal with the areas that caregivers struggle with as caregivers in order to help them feel better able to prepared to manage as caregivers. also, the investigators also hope to develop some beginning understanding of when is the best time to provide the program to stroke caregivers to be most helpful to them in their caregiving role.

Eligibility criteria:
informal unpaid family stroke caregivers inclusion criteria: informal unpaid family stroke caregivers * 18 years of age or older; * have provided care to stroke survivor within the home for at least 2 months; * have the ability to communicate in english; * live within central south ontario stroke region or the west gta stroke region. exclusion criteria: caregivers who: * paid to provide care; * are friends who provide care to stroke survivor; * are providing palliative care to stroke survivor within the home.

Keywords: stroke caregivers family caregivers stroke
multidisciplinary team approach: working together to improve glycemic control in hispanic adults diabetes

Conditions: Type 2 Diabetes

Summary: this study seeks to determine if a specialized multidisciplinary diabetes team (smdt) approach that incorporates the use of the chronic care model can be an effective method for improving glycemic control in hispanic adults with uncontrolled type 2 diabetes residing in the rio grande valley. the study will expand the current model of care used and focus on the multidimensional aspects that consist of physical, nutritional, educational and psychological needs of this underserved hispanic population residing in the rio grande valley.


Eligibility criteria:
inclusion criteria: * have physician-diagnosed type 2 diabetes * be self-identified as hispanic or latino * an a1c value between 9-14% within the last three months * english or spanish speaking exclusion criteria: * type 1 diabetes or gestational diabetes * cognitive impairment * prisoners or individuals under detention * unable to speak or understand english or spanish * medical history of the end-stage renal disease or undergoing dialysis.

Keywords: multidisciplinary team hispanic adults
safety, pharmacokinetics and preliminary efficacy study of cfz533 in patients with primary sjögren's syndrome

Conditions: Primary Sjögren's Syndrome

Summary: this study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of cfz533 monoclonal antibody in patients with primary sjögren's syndrome(pss)


Eligibility criteria:
inclusion criteria: * diagnosis of primary sjögren's syndrome * essdai score ≥ 6 exclusion criteria: * secondary sjögren's syndrome * receiving cyclosphosphamide, corticosteroid bolus with dose over 1 mg/kg, rituximab, belimunab, other immunosuppressives. * at significant risk for thromboembolic event * clinically significant systemic infection * significant elevated risk for infection

Keywords: sjögren's syndrome, cfz533, essdai
a study of meditation as a treatment for epilepsy

Conditions: Epilepsy

Summary: epileptic seizures may occur at times of stress and commonly increase life stress. this study will evaluate whether meditation improves seizure control and quality of life for individuals with uncontrolled epilepsy.

individuals who have uncontrolled epilepsy commonly experience disability, depression, anxiety and injuries from seizures. for such individuals, ideal treatments should improve quality of life through control of seizures and improved emotional state. meditation with cultivation of emotional balance is known to improve emotional state and may also benefit seizure control in some individuals. in this study, individuals with uncontrolled epilepsy will receive detailed training in meditation to determine whether the training leads to improvements in seizure control and various measures of emotion and quality of life.

Eligibility criteria:
inclusion criteria: * 6 or more seizures per month * ability to participate in meditation
xenon and therapeutical hypothermia after successful cardiopulmonary resuscitation

Conditions: Efficacy and Safety of Xenon Inhalation; Successful Cardiopulmonary Resuscitation; Addition to Therapeutical Hypothermia

Summary: in this clinical trial will be checked, whether 2 hour ventilation with xenon has neuroprotective effects in patients with out of hospital cardiac arrest and successful cardiopulmonary resuscitation

patients with out of hospital cardiac arrest and successful cardiopulmonary resuscitation will be randomized in two groups. first group (treatment group) will be inhalated with xenon within 2 hours in addition to therapeutical hypothermia. the second group (control group) will be treated with therapeutical hypothermia in accordance to international guidelines.

Eligibility criteria:
inclusion criteria: * patients with out of hospital cardiac arrest and successful cardiopulmonary resuscitation, which will be treated at department of internal medicine i, university hospital aachen exclusion criteria: * patients younger than 18 years * xenon allergy * pregnancy * high expired oxygen requirement (\>70%) in order to maintain adequate arterial oxygen saturation (spo2\>94%) at the beginning of treatment

Keywords: xenon inhalation therapeutical hypothermia patients after cardiopulmonary resuscitation efficacy safety
pain relief for ventilated patients with multiple rib fractures using the on-q pain relief system

Conditions: Rib Fractures

Summary: the purpose of this study is to find out if patients having the on-q post-op pain relief system for pain management of multiple rib fractures will require fewer ventilator days, and will need less iv pain medicine to control their pain, and as a result have improved respiratory function during their recovery. the standard of care for providing pain relief for rib fractures is to use an opioid drug that is injected into the vein but also has side effects. increased doses can lead to over sedation and consequently lead to difficulty with breathing. the on-q pain relief systems uses a local anesthetic under the skin. the anesthetic is called bupivicaine, and it is delivered from a thin tube approximately 10 inches long is tunneled under the skin along the back and parallel to the spine. the medication is stored in an elastic pump which delivers a slow continuous drip of medication from multiple holes in the tubing. subjects will be randomized to either standard intravenous opioid pain management or the on-q pain relief device with supplemental opioid medication if needed. the device will remain in use until the subjects are able to breathe without the ventilator.


Eligibility criteria:
inclusion criteria: * \> 18 years of age * 3 or more rib fractures * intubated ready for weaning from ventilator support * fi02 \< 50% * peep \< 10cm h2o exclusion criteria: * \< 18 years of age * pregnant * unable to communicate pain status * allergy to local anesthetics * coagulopathy * skin lesions or abnormalities from previous injury or surgery * \< 3 rib fractures

Keywords: rib fractures ventilator on-q analgesia
effects of cyclic variations in altitude conditioning (cvac) on wellness and activity measures

Conditions: Hypoxia

Summary: cyclic variation in altitude conditioning (cvac) is a new technique that uses a pod-like device to expose users to controlled fluctuations in air pressure. it is designed to promote quicker altitude acclimatization, thus promoting improvements in exercise capacity at altitude and, possibly, at sea level. however, over the past few years, anecdotal stories from users of the device suggest that the cvac treatments might be causing changes beyond the expected endurance exercise performance benefits. therefore, the purpose of the study is to obtain data on some of the previous anecdotal claims regarding the device (e.g. increases in strength, improved glucose tolerance, reduction of neuropathic pain and decreased joint swelling) as well as to obtain broad questionnaire data in order to identify more specific variables to investigate in future studies.


Eligibility criteria:
inclusion criteria: * healthy middle aged men at risk for metabolic syndrome exclusion criteria: * uncontrolled hypertension, * sensitive ears, * anything that would preclude person from sustaining rapid pressure changes
cognitive remediation therapy and schizophrenia

Conditions: Schizophrenia

Summary: objectives: the purpose of this study is to determine the impact of a new cognitive remediation therapy (crt) on cognition, social autonomy, symptoms and brain functioning in patients with schizophrenia.

methods: in a 2 arms blind study versus sham,80 patients with schizophrenia were enrolled in a program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means rehacom® software. measures of cognitive functioning using the cogtest® battery as well as social autonomy (social autonomy scale, eas) and schizophrenia symptoms (positive and negative syndrome scale, panss) were undertaken at the beginning and the end of the meetings of remediation. among those 80 participants, 30 patients to (15 active / 15 sham) were randomized to participate in an fmri study in order to investigate the impact of such crt program on brain functioning (n-back task before crt and 3 months later).

Eligibility criteria:
inclusion criteria: * schizophrenia (dsm iv criteria) * remitted symptoms * french language * informed consent exclusion criteria: * addiction, neurological disease * only for second randomized patient participating in mri study (n=30) : mri counterindications

Keywords: cognitive deficits
intrathecal morphine for analgesia in video-assisted thoracic surgery

Conditions: Pain, Postoperative

Summary: vats is widely used for diagnosis and treatment of intrathoracic conditions. despite many benefits, postoperative pain continues to be intense after vats. the optimal strategy for pain management has not been defined. in this randomized, placebo-controlled, double-blinded clinical investigation, investigators hypothesize that 5 mcg/kg intrathecal morphine will decrease postoperative analgesic consumption and reduce pain.

this is a randomized, placebo-controlled, double-blinded clinical trial. patients will be randomized into one of two groups. group a (placebo, control group) will receive intrathecal sterile normal saline and group b (morphine group) will receive 5mcg/kg preservative free intrathecal morphine. american pain society outcome questionnaire (aps-poq) will be administered to patients prior to discharge (see data sheet). patients will be followed up with a phone survey at 1 and 3 months after surgery to assess the presence, nature, and severity of chronic persistent surgical pain. the brief pain inventory is a reliable and valid measures of the interference of pain with physical functioning and will be used. additionally patients will be asked about use of pain medications

Eligibility criteria:
inclusion criteria: * age 18-80 years old * undergoing elective video-assisted thoracoscopic surgery for anatomical lung resection * general anesthesia with anticipated intraoperative extubation. exclusion criteria: * american society of anesthesiologists (asa) classification of 4 or 5 * anticipated postoperative intubation * significant liver disease * preoperative use of intravenous inotropes and/or vasopressor support * preoperative mechanical ventilation * preoperative use of mechanical circulatory support device (intraaortic balloon pump, ventricular assist device, extracorporeal membrane oxygenation) * severe pulmonary disease (home oxygen requirement and/or current oral steroid use) * morphine allergy * opioid or alcohol abuse * chronic pain * renal failure * inability to comprehend english language * bleeding disorder * abnormal preoperative coagulation * infection * patient refusal
unsupervised therapy after stroke in the home setting with a hand rehabilitation device (rehandybot)

Conditions: Stroke

Summary: the rehandybot is a robot for hand rehabilitation after stroke. the aims of this study are (1) to investigate the feasibility of unsupervised therapy with the rehandybot with stroke inpatients, first in a rehabilitation clinic and then at participants' home, (2) to evaluate the usability of the rehandybot (user interface, implemented exercises, and gaming environment, which were adapted for independent usage), and (3) to quantify the dose of additional robotic therapy that patients perform without supervision. the study consists of two primary phases. the first is a familiarization phase performed at the clinic, where therapists teach to the participants how to perform the exercises with the robot. then, if capable of training with the robot safely, after discharge from the clinic participants can bring the robot home and autonomously train with it. the hypothesis is that unsupervised therapy might be a possible way to increase therapy dose for stroke patients, with the potential to further improve recovery of hand function, with minimal additional burden for therapists and for the healthcare system.


Eligibility criteria:
inclusion criteria: * informed consent signed by the subject; * female and male patients between 18 and 90 years old; * acute/subacute stroke (recruitment within 12 weeks from stroke onset); * pre-stroke modified rankin score ≤ 1; * national institutes of health stroke scale (nihss) ≥ 1 in at least one of the items regarding motor functions, sensory functions and ataxia; * possibility (e.g., enough space) to set up the rehandybot at home. exclusion criteria: * modified ashworth scale \> 2 for one or more of the following muscles: shoulder adductors, forearm pronator and supinator, flexors and extensors of elbow, wrist and fingers; * moderate to severe aphasia: goodglass-kaplan's scale \< 3; * moderate to severe cognitive deficits: levels of cognitive functioning-revised (lcf-r) \< 9; * functional impairment of the upper limb due to other pathologies; * severe pain in the affected arm: visual analogue scale for pain (vasp) ≥ 5; * other pathologies which may interfere with the study; * pacemakers and other active implants; * after discharge the patient will go to an assisted living facility (e.g., care home).

Keywords: stroke hand impairment robot-assisted therapy unsupervised therapy neurorehabilitation